Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch
Mirjam Simoons1,2,3, Adrie Seldenrijk2,4, Hans Mulder1,5
1Department of Clinical Pharmacy, Wilhelmina Hospital Assen, Assen, The Netherlands.
Insights
This study provides guidelines for electrocardiogram (ECG) screening during antidepressant treatment to identify patients at risk for cardiac arrhythmias. Recommendations focus on selecting high-risk individuals for monitoring to prevent sudden cardiac death.
Area of Science:
- Clinical Cardiology
- Psychopharmacology
- Preventive Medicine
Background:
- Lack of specific international/national guidelines for ECG screening during antidepressant therapy.
- Need for clear criteria to assess cardiac arrhythmia and sudden death risk.
- Existing recommendations for QT(c) prolongation lack concrete patient selection guidance.
Purpose of the Study:
- To develop consensus-based guidelines for ECG screening and monitoring during antidepressant treatment.
- To identify patients at high risk for cardiac arrhythmias and sudden death.
- To provide practical recommendations for clinical practice.
Main Methods:
- Literature review to identify risk factors for cardiac events during antidepressant use.
- Multidisciplinary expert panel consensus development.
- Formulation of evidence-based and expert-opinion-driven recommendations.
Main Results:
- Identified key risk factors for QTc prolongation and cardiac events.
- Developed a practical screening and monitoring strategy for antidepressant users.
- Recommended ECG screening before and during treatment for high-risk patients.
Conclusions:
- Established clear criteria for identifying high-risk patients needing ECG monitoring.
- Guidelines address antidepressant-associated cardiac risks, particularly QTc prolongation.
- Aims to improve patient safety and reduce sudden cardiac death risk.
Abstract:
Currently, there is a lack of international and national guidelines or consensus documents with specific recommendations for electrocardiogram (ECG) screening and monitoring during antidepressant treatment. To make a proper estimation of the risk of cardiac arrhythmias and sudden (cardiac) death during antidepressant use, both the drug and patient-specific factors should be taken into account; however, solid evidence on how this should be done in clinical practice is lacking. Available recommendations on the management of QT(c) prolongation (with antidepressant treatment) emphasize that special attention should be given to high-risk patients; however, clinicians are in need of more concrete suggestions about how to select patients for ECG screening and monitoring. Based on a review of the literature, a Dutch multidisciplinary expert panel aimed to formulate specific guidelines to identify patients at risk for cardiac arrhythmias and sudden death by developing a consensus statement regarding ECG screening before, and monitoring during, antidepressant use. We first reviewed the literature to identify the relative risks of various risk factors on cardiac arrhythmia and sudden (cardiac) death during antidepressant use. These relative contributions of risk factors could not be determined since no systematic reviews or meta-analyses quantitatively addressed this topic. Because evidence was insufficient, additional expert opinion was used to formulate recommendations. This resulted in readily applicable recommendations for clinical practice for selection of high-risk patients for ECG screening and monitoring. ECG screening and monitoring is recommended before and following the start of QTc-prolonging antidepressants in the presence of vulnerability to QTc prolongation or two or more risk factors (age > 65 years, female sex, concomitant use of a QTc-prolonging drug or concomitant use of a drug that influences the metabolism of a QTc-prolonging drug, cardiac disease, excessive dosing and specific electrolyte disturbances).
More Related Videos
Related Concept Videos
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:25Correlation between ECG and Cardiac Cycle
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...
02:55The Evidence for Evolution
01:24Drug Toxicity: Risk factors
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:29Therapeutic Drug Monitoring: Affecting Factors